APRE
Aprea Therapeutics, Inc.NASDAQHealthcare$0.72+1.65%ClosedMarket Cap: $4.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.41
P/S
15.89
EV/EBITDA
0.77
DCF Value
$2.25
FCF Yield
-288.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.4%
Operating Margin
-4631.1%
Net Margin
-4409.2%
ROE
-93.7%
ROA
-79.1%
ROIC
-100.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $3.3K | 131325.4% | $-2.6M | $-2.5M | $-0.32 | — |
| FY 2025 | $285.8K | 92.4% | $-13.2M | $-12.6M | $-1.93 | — |
| Q3 2025 | $1.8K | -193.8% | $-3.1M | $-3.0M | $-0.47 | — |
| Q2 2025 | $118.1K | -1519.0% | $-3.4M | $-3.2M | $-0.53 | — |
| Q1 2025 | $162.5K | -1428.4% | $-4.1M | $-3.9M | $-0.66 | — |
| Q4 2024 | $205.8K | -1046.2% | $-3.2M | $-2.9M | $-0.49 | — |
| FY 2024 | $1.5M | -523.2% | $-14.3M | $-13.0M | $-2.35 | — |
| Q3 2024 | $354.6K | -702.7% | $-4.1M | $-3.8M | $-0.64 | — |
| Q2 2024 | $561.6K | -355.4% | $-3.8M | $-3.5M | $-0.58 | — |
| Q1 2024 | $380.6K | -320.5% | $-3.1M | $-2.8M | $-0.67 | — |
| Q4 2023 | $14.1K | -14434.2% | $-3.7M | $-3.4M | $-0.92 | — |
| FY 2023 | $583.2K | 98.8% | $-15.5M | $-14.3M | $-3.95 | — |